美罗培南治疗老年院内获得性重症肺炎86例临床疗效及安全性评价

目的评价美罗培南治疗老年重症院内获得性肺炎的临床疗效及其安全性。方法美罗培南治疗老年重症肺炎共86例,观察临床疗效、细菌学疗效及其安全性。剂量为美罗培南0.5～1.0g静脉滴注,每8或12h1次,疗程5～14d。结果美罗培南治疗老年重症HAP的临床痊愈率和临床有效率分别为83.7%和90.7%,细菌敏感率和细菌清除率分别为87.6%和84.8%,不良反应总发生率12.8%(11/86),包括腹泻3例、并发真菌感染8例,肠道艰难杆菌感染1例,未发现其他毒副作用。结论美罗培南是治疗老年重症院内获得性肺炎疗效确切、较为安全的抗菌药物,可作为重症肺炎的经验性用药。但应密切监测细菌耐药性的变化,及时调整治疗方案。

Efficacy and safety evaluation of meropenem in 86 elder patients with severe hospital acquired pneumonia

Objective To evaluate the efficacy and safety of meropenem for the treatment of elderly patients with severe hospital-acquired pneumonia. Methods A total of 86 patients with severe hospital-acquired pneumonia(HAP) in Beijing Hospital were treated with meropenem (0.5g-1.0g iv q8h-12h x 5~14d) in an open clinical study. Results The total efficacy rate of meropenem was 90.7% with cure rate of 83.7%,bacteria elimination rates were 84.8%. The drug related adverse events was 12.8%(11/86)., includeing diarrea, complicating fungal infections and clostridium difficle intestinal infection. Conclusions The study shows that meropenem is well tolerated and effective in treating severe hospital-acquired pneumonia of elderly patients.